🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a nonrandomized, open phase I dose escalation and extension clinica...
Status
Unknown
Location
Zhangli
Start Date
2022-09-21
Trial ID
NCT05489731
Treatments Being Tested
Osimertinib combined with savolitinib in the treatment of EGFR mutated osim...
Status
Recruiting
Location
Qingdao Central Hospital
Start Date
2025-01-01
Trial ID
NCT07322783
Treatments Being Tested
The study is being conducted to evaluate the safety, tolerability and effic...
Status
Recruiting
Location
Shanxi Cancer hospital
Start Date
2025-03-28
Trial ID
NCT06895928
To assess the pharmacokinetics of TY-9591 tablets and Osimertinib Mesylate ...
Status
Completed
Location
Hunan Provincial Tumor Hospital
Start Date
2021-04-30
Trial ID
NCT04798638
Treatments Being Tested
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), in...
Status
Unknown
Location
Peking University Third Hospital
Start Date
2016-05
Trial ID
NCT03050411
Treatments Being Tested
This phase II clinical study is a study to explore the efficacy and safety ...
Status
Recruiting
Location
Shanghai East Hospital
Start Date
2024-07-31
Trial ID
NCT06498986
Treatments Being Tested
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 f...
Status
Active Not Recruiting
Location
Shanghai Pulmonary Hospital
Start Date
2023-07-19
Trial ID
NCT05880706
Treatments Being Tested
This study is a Phase III, international, multicenter, randomized, controll...
Status
Recruiting
Location
Guangdong Provincial People's Hospital
Start Date
2024-09-26
Trial ID
NCT06970639
TQ-B3525 tablet is a new α/δ dual inhibitor phosphatidylinositol 3-kinase i...
Status
Unknown
Location
Sun-Yat-Sen University Cancer Center
Start Date
2022-03-11
Trial ID
NCT05284994
Treatments Being Tested
To evaluate the efficacy and safety of glumetinib combined with osimertinib...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2025-04-01
Trial ID
NCT06908772
Treatments Being Tested